Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD. - Full Text View

Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD.

This study has been completed.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00041483

Purpose

The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.

Condition	Intervention	Phase
Macular Degeneration	Drug: Anecortave Acetate	Phase III

Genetics Home Reference related topics:

X-linked juvenile retinoschisis

MedlinePlus related topics:

Macular Degeneration

ChemIDplus related topics:

Verteporfin Anecortave acetate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Single Group Assignment, Safety/Efficacy Study

Official Title:	Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD.

Further study details as provided by Alcon Research:

Primary Completion Date:

September 2005 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Patients of any race, either gender, aged 50 years and above, diagnosed with subfoveal CNV due to AMD with best corrected logMAR visual acuity of 20/40 (snellen equivalent) to 20/400 (Snellen equivalent) in the study eye. Clinically relevant concomitant diseases will be excluded.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00041483

Locations


United States, Texas
	US, Canada, Australia and Europe
	Ft. Worth, Texas, United States

Sponsors and Collaborators

Alcon Research

More Information

Click here for more information about this study: A Phase III Clinical Trial for AMD: Information for Potential Participants This link exits the ClinicalTrials.gov site

This link exits the ClinicalTrials.gov site

Study ID Numbers:	C-01-99
First Received:	July 9, 2002
Last Updated:	July 21, 2008
ClinicalTrials.gov Identifier:	NCT00041483
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alcon Research:

AMD

age-related macular degeneration

Anecortave

Acetate

Wet form of age-related macular degeneration

Study placed in the following topic categories:

Eye Diseases

Verteporfin

Retinal Degeneration

Macular Degeneration

Retinal Diseases

Retinal degeneration

ClinicalTrials.gov processed this record on September 05, 2008